Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the efficacy and safety of AD-208.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Addpharma Inc.
NCT07080931 · Androgenetic Alopecia
NCT07012486 · Androgenetic Alopecia (AGA)
NCT06527365 · Androgenetic Alopecia, AGA, and more
NCT07011485 · Alopecia, Androgenetic, Baldness, and more
NCT07076706 · Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA)
The Catholic University of Korea, Eunpyeong St. Mary's Hospital
Seoul
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions